SCHEMBL10042015

SCHEMBL10042015

CC1(C)CNC(=O)c2sc(-c3ccnc4c3ccn4-c3ccccc3)nc2C1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KDM4E B2RXH2 1/20 0.46
ATAD2 Q6PL18 1/20 0.43
TSHR P16473 1/20 0.41
HTT P42858 1/20 0.40
HIF1A Q16665 1/20 0.40
MAP2K2 P36507 1/20 0.38
MAP2K1 Q02750 1/20 0.38
PIK3CD O00329 6/20 0.37
PIK3CB P42338 5/20 0.37
PIK3CG P48736 5/20 0.37
PIK3CA P42336 2/20 0.37
MGAM O43451 3/20 0.36
GAA P10253 3/20 0.36
SI P14410 3/20 0.36
MGAM2 Q2M2H8 3/20 0.36
CYP11B2 P19099 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10070729 0.85 ATAD2 (0.49) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL10070727 0.84 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL10042017 0.81 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL504077 0.75 ATAD2 (0.49) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL504084 0.68 PIK3CD (0.70) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL2472341 0.68 ATAD2 (0.52) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL31616006 0.65 CDK2 (0.48) MAP2K2MAP2K1PIK3CAGAA
SCHEMBL3588586 0.64 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL302929 0.64 ATAD2 (0.70) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E
SCHEMBL3574427 0.63 ATAD2 (0.48) ALDH1A1SMN1; SMN2NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130267498-A1 COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2013-10-10 US disclosed
US-8399458-B2 Compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-03-19 US disclosed
US-20120028965-A1 COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028965-A1 COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K6, MAP3K1 ALDH1A1 4106/4885SMN1; SMN2 1938/4885NPC1 1136/4885
US-20130267498-A1 COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS MAP3K20, MAP3K6, MAP3K1 ALDH1A1 4106/4885SMN1; SMN2 1938/4885NPC1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.